At least 4 Sprague-Dawley rats/sex were dosed orally by gavage with 100 mg/kg of CPPU-UL-phenyl-(14)C (radiochemical purity: 99.16%; specific activity: 28.04 mCi/mmol) fortified with unlabeled Forchlorfenuron technical (purity: 98.2%). ... The primarily metabolite recovered in the urine was CPPU-sulfate with substitution on the phenyl ring. It represented 84 and 57% of the administered dose for the males and females, respectively. Other metabolites were products of phenyl ring hydroxylations as well. Hydroxyl-CPPU was the predominant metabolite recovered from the feces with 11 and 18% of the administered dose recovered from the males and females, respectively.
来源:Hazardous Substances Data Bank (HSDB)
毒理性
致癌物分类
对人类不具有致癌性（未被国际癌症研究机构IARC列名）。
No indication of carcinogenicity to humans (not listed by IARC).
/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/
/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/
来源:Hazardous Substances Data Bank (HSDB)
毒理性
解毒与急救
/SRP:/ 高级治疗：对于无意识、严重肺水肿或严重呼吸困难的病人，考虑进行口咽或鼻咽气管插管以控制气道。使用气囊面罩装置的正压通气技术可能有益。考虑使用药物治疗肺水肿……。对于严重的支气管痉挛，考虑给予β激动剂，如沙丁胺醇……。监测心率和必要时治疗心律失常……。开始静脉输注D5W /SRP: "保持开放"，最低流量/。如果出现低血容量的迹象，使用0.9%生理盐水（NS）或乳酸林格氏液。对于伴有低血容量迹象的低血压，谨慎给予液体。注意液体过载的迹象……。使用地西泮或劳拉西泮治疗癫痫……。使用丙美卡因氢氯化物协助眼部冲洗……。 /Poisons A and B/
/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/
/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ Ten male and ten female mice/dose were offered food containing each of the following concentrations of SKW 20010 (/forchlorfenuron/ 100% purity): 0, 900, 1800, 3500 or 7000 ppm. Food containing the test article was offered ad libitum for 90 days. Mean consumption of test compound at the 5 dosage levels in ascending order was males/females 162/206, 332/411, 609/788 and 1288/1683 mg/kg/day. There was no mortality and clinical signs were limited to a higher incidence of scabbing and reddening of the ears of treated males; however, there was no dose-response for this clinical sign and it was not observed in females. Only animals fed 7000 ppm had mean body weights which were lower than controls. This was true for both males and females, starting at 3 weeks. However, only in the case of males during the ninth week was the difference statistically significant. Food consumption was significantly lower for animals fed the highest dose, for a total of 4 weeks in the case of males and for one week in the case of females. At 3500 ppm both sexes suffered a single week with significantly lower food consumption. Tests in clinical pathology at 90 days revealed no convincing compound-related effects. Platelets were elevated for all males fed the test compound, but these increases were not statistically significant, showed no dose-response, and were absent from treated females. A similar pattern was noted for elevated urea nitrogen in treated males with one difference: the increase at 900 ppm was statistically significant. Bilirubin was elevated for both males and females at 7000 and 3500 ppm; however, only the increases at 7000 ppm for females and 3500 ppm for males were statistically significant. At necropsy, 4 males and 4 females were noted as having gray lacrimal glands, compared to none in controls. However, there was no dose-response for this endpoint. Free organ weights were not significantly different for treated versus control animals. In contrast, when organ weights were normalized to final bodyweights, significant increases in liver weights were identified in males at 3500 and 7000 ppm and in females at 7000 ppm. Normalized liver weights were also elevated in males at the two lower doses (though not significantly), perhaps suggesting a dose-response. However, since free liver weights were not significantly different from controls and microscopic examination of stained liver sections were negative, it is doubtful that the test compound caused liver enlargement. Lastly, the normalized kidney weights of females fed the highest dose were significantly elevated compared to controls, and microscopic examination of that organ revealed an increased incidence of infiltration of lymphocytes into the interstitium and pelvis (true for both males and females). However, since these infiltration events were almost always graded as minimal, and free kidney weights were not significantly elevated compared to controls, the case for a compound-related effect on the kidneys is weak.
In both the main study and the biliary excretion study, at least 4 Sprague-Dawley rats/sex were dosed orally by gavage with 100 mg/kg of CPPU-UL-phenyl-(14)C (radiochemical purity: 99.16%; specific activity: 28.04 mCi/mmol) fortified with unlabeled Forchlorfenuron technical (purity: 98.2%). In the main study, urine, feces and air samples were collected periodically for 7 days post-dose. In the biliary excretion study, bile samples were collected periodically via the bile duct cannula up to 72 hours post-dose. The primary route of excretion was in the urine ((M) urine: 79%, feces: 16%, (F) urine: 68%, feces: 28%). During the 1st 24 hours post-dose, 82% of the radiolabel was recovered from the males and 66% from the females. Less than 0.1% of the administered dose was recovered in the air. The excretory half-lives ranged from 13 to 16 hours for both sexes for both the urine and feces. Recovery in the tissues at 7 days post dose represented less than 1% of the administered dose. In the biliary excretion study, 23 and 20% of the administered radiolabel were recovered in the bile from the males and females, respectively. However, the absorption kinetics could not be readily assessed because no urine or feces samples were collected simultaneously from these study animals.
来源:Hazardous Substances Data Bank (HSDB)
吸收、分配和排泄
被叶子、茎、子叶和已发芽的种子吸收。
Absorbed by leaves, stem, cotyledon and germinated seeds.
[EN] ACC INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE L'ACC ET UTILISATIONS ASSOCIÉES
申请人：GILEAD APOLLO LLC
公开号：WO2017075056A1
公开（公告）日：2017-05-04
The present invention provides compounds I and II useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, and methods of using the same.
[EN] BICYCLYL-SUBSTITUTED ISOTHIAZOLINE COMPOUNDS<br/>[FR] COMPOSÉS ISOTHIAZOLINE SUBSTITUÉS PAR UN BICYCLYLE
申请人：BASF SE
公开号：WO2014206910A1
公开（公告）日：2014-12-31
The present invention relates to bicyclyl-substituted isothiazoline compounds of formula (I) wherein the variables are as defined in the claims and description. The compounds are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to a method for controlling invertebrate pests by using these compounds and to plant propagation material and to an agricultural and a veterinary composition comprising said compounds.
A tetrazolinone compound of formula (1):
wherein R
1
and R
2
each independently represents a hydrogen atom, etc.;
R
3
represents a C1-C6 alkyl group, etc.; R
4
, R
5
, and R
6
each independently represents a hydrogen atom, etc.; A represents a C6-C16 aryl group optionally having one or more atoms or groups selected from Group P, etc.; Q represents the following group Q1, etc.; and
X represents an oxygen atom or a sulfur atom, has excellent control activity against pests.
The present invention provides triazole compounds useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, and methods of using the same.
本发明提供了三唑化合物，可用作乙酰辅酶A羧化酶（ACC）的抑制剂，以及其组合物和使用方法。
Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto
申请人：Dow AgroSciences LLC
公开号：US20180279612A1
公开（公告）日：2018-10-04
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions containing such molecules, and processes of using such pesticidal compositions against such pests. These pesticidal compositions may be used, for example, as acaricides, insecticides, miticides, molluscicides, and nematicides. This document discloses molecules having the following formula (“Formula One”).
